These findings are encouraging and spurred the researchers to develop small-molecule inhibitors that could target the Tudor domain and α-helix linker, which act as an active site in SND1 protein as a novel treatment of HCC. This evidence concerns the gene SND1 and hepatocellular carcinoma.